BR0108411A - Formulação contraceptiva masculina compreendendo noretisterona - Google Patents
Formulação contraceptiva masculina compreendendo noretisteronaInfo
- Publication number
- BR0108411A BR0108411A BR0108411-9A BR0108411A BR0108411A BR 0108411 A BR0108411 A BR 0108411A BR 0108411 A BR0108411 A BR 0108411A BR 0108411 A BR0108411 A BR 0108411A
- Authority
- BR
- Brazil
- Prior art keywords
- norethisterone
- male contraceptive
- contraceptive formulation
- testosterone
- men
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title abstract 5
- 239000000203 mixture Substances 0.000 title abstract 5
- 239000002583 male contraceptive agent Substances 0.000 title abstract 4
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 title abstract 4
- 229940053934 norethindrone Drugs 0.000 title abstract 3
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 abstract 2
- 206010003883 azoospermia Diseases 0.000 abstract 2
- 239000000583 progesterone congener Substances 0.000 abstract 2
- IMONTRJLAWHYGT-ZCPXKWAGSA-N Norethindrone Acetate Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@](C#C)(OC(=O)C)[C@@]1(C)CC2 IMONTRJLAWHYGT-ZCPXKWAGSA-N 0.000 abstract 1
- APTGJECXMIKIET-WOSSHHRXSA-N Norethindrone enanthate Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@](C#C)(OC(=O)CCCCCC)[C@@]1(C)CC2 APTGJECXMIKIET-WOSSHHRXSA-N 0.000 abstract 1
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testosterone Natural products O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 abstract 1
- 239000003098 androgen Substances 0.000 abstract 1
- 230000001548 androgenic effect Effects 0.000 abstract 1
- 230000001076 estrogenic effect Effects 0.000 abstract 1
- 229960001652 norethindrone acetate Drugs 0.000 abstract 1
- 229960002082 norethindrone enanthate Drugs 0.000 abstract 1
- 208000008634 oligospermia Diseases 0.000 abstract 1
- 230000021595 spermatogenesis Effects 0.000 abstract 1
- 229960003604 testosterone Drugs 0.000 abstract 1
- -1 testosterone ester Chemical class 0.000 abstract 1
- UDSFVOAUHKGBEK-CNQKSJKFSA-N testosterone undecanoate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CCCCCCCCCC)[C@@]1(C)CC2 UDSFVOAUHKGBEK-CNQKSJKFSA-N 0.000 abstract 1
- 229960000746 testosterone undecanoate Drugs 0.000 abstract 1
- 150000003515 testosterones Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
- Orthopedics, Nursing, And Contraception (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
"FORMULAçãO CONTRACEPTIVA MASCULINA COMPREENDENDO NORETISTERONA". Uma formulação para contracepção masculina compreendendo uma progestina possuindo ambas as propriedades androgênicas e estrogênicas é bastante eficaz para a supressão da espermatogênese em homens. A progestina Noretisterona (NET), particularmente seus derivados Acetato de Noretisterona e Enantato de Noretisterona em doses suficientes induzem oligozoospermia ou azoospermia em homens. Formulações também compreendendo um androgênio, tal como um derivado de testosterona como por exemplo um éster de testosterona, particularmente undecanoato de testosterona, são formulações contraceptivas masculinas especialmente eficazes.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US50372900A | 2000-02-15 | 2000-02-15 | |
| EP00200493 | 2000-02-15 | ||
| PCT/IB2001/000188 WO2001060376A1 (en) | 2000-02-15 | 2001-02-15 | Male contraceptive formulation comprising norethisterone |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0108411A true BR0108411A (pt) | 2003-03-11 |
Family
ID=26071832
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0108411-9A BR0108411A (pt) | 2000-02-15 | 2001-02-15 | Formulação contraceptiva masculina compreendendo noretisterona |
Country Status (26)
| Country | Link |
|---|---|
| EP (2) | EP1666044B1 (pt) |
| JP (1) | JP2003522795A (pt) |
| KR (1) | KR20020086905A (pt) |
| CN (1) | CN1423560A (pt) |
| AT (2) | ATE355844T1 (pt) |
| AU (1) | AU2001230447A1 (pt) |
| BG (1) | BG107066A (pt) |
| BR (1) | BR0108411A (pt) |
| CA (1) | CA2398063A1 (pt) |
| CY (1) | CY1106639T1 (pt) |
| CZ (1) | CZ20022691A3 (pt) |
| DE (2) | DE60127103T2 (pt) |
| DK (1) | DK1267885T3 (pt) |
| EE (1) | EE200200454A (pt) |
| ES (1) | ES2282230T3 (pt) |
| HK (1) | HK1049442B (pt) |
| HU (1) | HUP0300128A3 (pt) |
| IL (1) | IL151219A0 (pt) |
| MX (1) | MXPA02007675A (pt) |
| NO (1) | NO20023607L (pt) |
| PL (1) | PL357185A1 (pt) |
| PT (1) | PT1267885E (pt) |
| RU (1) | RU2002124602A (pt) |
| SI (1) | SI1267885T1 (pt) |
| SK (1) | SK11602002A3 (pt) |
| WO (1) | WO2001060376A1 (pt) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10234525A1 (de) * | 2002-07-25 | 2004-02-05 | Schering Ag | Zusammensetzung, enthaltend ein androgenes 11ß-Halogensteroid und ein Gestagen sowie männliches Kontrazeptivum auf Basis dieser Zusammensetzung |
| TW200404552A (en) * | 2002-05-30 | 2004-04-01 | Akzo Nobel Nv | Self administered contraception |
| PL373808A1 (en) | 2002-07-24 | 2005-09-19 | Schering Aktiengesellschaft | Microbiological method for the production of 7 alpha-substituted 11 alpha-hydroxysteroids |
| CN1671394A (zh) * | 2002-07-25 | 2005-09-21 | 舍林股份公司 | 包含雄激素性11β－卤素甾体和孕激素的组合物以及基于该组合物的雄性避孕药 |
| CN101352443B (zh) * | 2007-07-23 | 2011-01-12 | 中国科学院动物研究所 | 哺乳动物雄性不育剂 |
| US10912762B2 (en) | 2018-03-23 | 2021-02-09 | Laboratoires Major | Non-hormonal compositions and methods for male contraception |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2714420A1 (de) * | 1976-06-01 | 1977-12-08 | Int Pregnancy Advisory Service | Antikonzeptionsmittel zur verabreichung an mann und frau in einer gemeinsamen verabreichungspackung |
| US4210644A (en) | 1978-02-23 | 1980-07-01 | The Johns Hopkins University | Male contraception |
| US5035891A (en) | 1987-10-05 | 1991-07-30 | Syntex (U.S.A.) Inc. | Controlled release subcutaneous implant |
| CN1102095A (zh) * | 1993-10-30 | 1995-05-03 | 浙江医科大学 | 长效雄激素类制剂——十一酸睾丸注射液 |
| DE19650352A1 (de) * | 1996-12-04 | 1998-07-30 | Jenapharm Gmbh | Oral wirksames Kombinationspräparat zur Kontrazeption für den Mann |
-
2001
- 2001-02-15 JP JP2001559472A patent/JP2003522795A/ja active Pending
- 2001-02-15 EP EP06075322A patent/EP1666044B1/en not_active Expired - Lifetime
- 2001-02-15 MX MXPA02007675A patent/MXPA02007675A/es unknown
- 2001-02-15 EP EP01902590A patent/EP1267885B8/en not_active Expired - Lifetime
- 2001-02-15 DE DE60127103T patent/DE60127103T2/de not_active Expired - Lifetime
- 2001-02-15 IL IL15121901A patent/IL151219A0/xx unknown
- 2001-02-15 AT AT01902590T patent/ATE355844T1/de active
- 2001-02-15 AU AU2001230447A patent/AU2001230447A1/en not_active Abandoned
- 2001-02-15 RU RU2002124602/15A patent/RU2002124602A/ru not_active Application Discontinuation
- 2001-02-15 WO PCT/IB2001/000188 patent/WO2001060376A1/en active IP Right Grant
- 2001-02-15 DK DK01902590T patent/DK1267885T3/da active
- 2001-02-15 SI SI200130726T patent/SI1267885T1/sl unknown
- 2001-02-15 DE DE60142647T patent/DE60142647D1/de not_active Expired - Lifetime
- 2001-02-15 PT PT01902590T patent/PT1267885E/pt unknown
- 2001-02-15 AT AT06075322T patent/ATE474580T1/de not_active IP Right Cessation
- 2001-02-15 BR BR0108411-9A patent/BR0108411A/pt not_active IP Right Cessation
- 2001-02-15 PL PL01357185A patent/PL357185A1/xx not_active Application Discontinuation
- 2001-02-15 CN CN01808041A patent/CN1423560A/zh active Pending
- 2001-02-15 KR KR1020027010715A patent/KR20020086905A/ko not_active Application Discontinuation
- 2001-02-15 CA CA002398063A patent/CA2398063A1/en not_active Abandoned
- 2001-02-15 HU HU0300128A patent/HUP0300128A3/hu unknown
- 2001-02-15 SK SK1160-2002A patent/SK11602002A3/sk unknown
- 2001-02-15 EE EEP200200454A patent/EE200200454A/xx unknown
- 2001-02-15 CZ CZ20022691A patent/CZ20022691A3/cs unknown
- 2001-02-15 ES ES01902590T patent/ES2282230T3/es not_active Expired - Lifetime
-
2002
- 2002-07-30 NO NO20023607A patent/NO20023607L/no not_active Application Discontinuation
- 2002-09-05 BG BG107066A patent/BG107066A/xx unknown
-
2003
- 2003-03-04 HK HK03101578.5A patent/HK1049442B/zh not_active IP Right Cessation
-
2007
- 2007-06-05 CY CY20071100743T patent/CY1106639T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20032805D0 (no) | Preparater av östrogensyklodekstrinkomplekser | |
| HUP0102483A2 (hu) | Androszt-5-én-3béta, 17béta-diolt tartalmazó gyógyszerkészítmények | |
| AR073972A2 (es) | Composiciones farmaceuticas para el tratamiento de carencias estrogenicas en la menopausia y para la prevencion de la osteoporosis en mujeres menopausicas | |
| CY1106639T1 (el) | Τυποποιηση αντισυλληπτικου για ανδρες που περιλαμβανει νορεθιστερονη | |
| WO2001003687A3 (en) | Method and compositions for inhibiting biosynthesis or bioactivity of endogenous steroid sex hormones in humans | |
| HUP0200173A2 (en) | Combined use of estrogen and progestogen, norethindrone acetate and ethinyl estradiol for preparing pharmaceutical compositions for preventing and treating skin aging and acne | |
| PE20080995A1 (es) | 18-metil-19-nor-androst-4-en-17,17-espiroeteres(18-metil-19-nor-20-espirox-4-en-3-onas), asi como preparaciones farmaceuticas que los contienen | |
| DE59805902D1 (de) | Nichtestrogene derivate des estradiols mit antioxidativer aktivität | |
| WO2004006936A8 (en) | Pharmaceutical composition comprising estetrol derivatives for use in cancer therapy | |
| WO2001040255A3 (en) | 14,15-beta-methylene substituted androgens | |
| MX2019014677A (es) | Compuestos de estra-1,3,5(10)-trien-17-ona sustituida con 15.beta.-[3-propanamido] y sus 17-oximas para usarse en la inhibicion de 17.beta.-hidroxiesteroides deshidrogenasas. | |
| AR027526A1 (es) | Formulacion anticonceptiva masculina que comprende noretisterona | |
| CR6627A (es) | Nuevo medicamento contraceptivo y su modo de preparacion | |
| JP2003522795A5 (pt) | ||
| HUP0301592A2 (hu) | 16alfa-metil- vagy etil-szubsztituált ösztrogének és ezeket tartalmazó gyógyszerkészítmények | |
| AR048829A1 (es) | 17alfa - fluoroesteroides con actividad inhibidora de 5 alfa-reductasa; composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamiento de enfermedades cancerosas influidas por androgenos. | |
| HK1060135A1 (en) | 4-Halogenated 17-methylene steroids, method for the production thereof and pharmaceutical compositions containing these compounds | |
| PE20020709A1 (es) | Composiciones de complejos de estrogeno-ciclodextrina | |
| CO6270329A2 (es) | Uso de gestageno en combinacion con un estrogeno y uno o varios excipientes / portadores farmaceuticamente acepptables para la anticoncepcion oral sin lactosa | |
| PL1910398T3 (pl) | 17-alfa-podstawione pochodne estradiolu wykazujące działanie gojenia ran |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 4A, 5A, 6A E 7A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1963 DE 19.08.2008. |